	US 11,779,630 B2
	Peptides and methods of using the same
Dana Austin, Manassas, VA (US); and Cohava Gelber, Manassas, VA (US)
Assigned to SERPIN PHARMA, LLC, Manassas, VA (US)
Appl. No. 17/753,013
Filed by SERPIN PHARMA, LLC, Manassas, VA (US)
PCT Filed Jul. 6, 2021, PCT No. PCT/US2021/040572 § 371(c)(1), (2) Date Feb. 15, 2022, PCT Pub. No. WO2022/010939, PCT Pub. Date Jan. 13, 2022.
Claims priority of provisional application 62/705,591, filed on Jul. 6, 2020.
Prior Publication US 2022/0265761 A1, Aug. 25, 2022
Int. Cl. A61K 38/10 (2006.01); A61P 25/04 (2006.01); A61P 25/28 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01); A61P 37/08 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01); A61P 29/00 (2006.01)

CPC A61K 38/10 (2013.01) [A61P 1/00 (2018.01); A61P 11/00 (2018.01); A61P 11/06 (2018.01); A61P 17/00 (2018.01); A61P 25/04 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 31/14 (2018.01); A61P 31/18 (2018.01); A61P 37/08 (2018.01)]

6 Claims

1. A method of treating a subject that suffers from a disease or condition associated with thymic stromal lymphopoietin (TSLP), comprising administering to the subject an effective amount of a composition comprising a serine protease inhibitor (SERPIN) peptide or a fusion thereof, wherein the SERPIN peptide comprises the amino acid sequence of VKFNKPFVFL(Nle)IEQNTK (SEQ ID NO: 35), wherein the disease or condition associated with TSLP is asthma, atopic dermatitis, allergic rhinoconjunctivitis, eosinophilic esophagitis (EoE), or rheumatoid arthritis.